<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75479">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812044</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00033000</org_study_id>
    <nct_id>NCT01812044</nct_id>
  </id_info>
  <brief_title>Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery</brief_title>
  <official_title>Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if local anesthetic, either a subtenons injection
      (an injection just beneath the surface tissue of the eye) or a topical ophthalmic gel
      (applied directly on the surface of the eye) given at the end of strabismus surgery reduces
      postoperative pain.   Some surgeons routinely use either the subtenon and/or topical
      anesthetic for pain at the end of strabismus surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Average pain score over the first 30 post-operative minutes using the CHEOPS scale</measure>
    <time_frame>0-30 minutes post-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain will be assessed by a masked observer using the Children's Hospital Eastern Ontario Pain Scale (CHEOPS) scale.  Pain is rated every 5 minutes for the first 30 minutes postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak pain score in the first 30 minutes</measure>
    <time_frame>0-30 minutes post-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>This secondary outcome will include the peak pain score in the first 30 minutes. Pain will be assessed by masked observers, using the CHEOPS scale.  Pain is rated every 5 minutes for the first 30 minutes postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total narcotic and anti-emetic use during post-operative recovery</measure>
    <time_frame>Total time in post-operative recovery - up to 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This secondary outcome will include total narcotic use, total anti-emetic use, and nausea or vomiting gathered from the anesthesia report from the Anesthesiologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative postoperative behavior score on the PHBQ (post hospitalization behavioral questionnaire)</measure>
    <time_frame>1 week (+/- 3 days) post operatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>This secondary outcome will determine the negative postoperative behaviors based on the PHBQ questionnaire given to the parents of the child 1 week (+/- 3 days) post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>30 minutes post-operative to discharge home</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain scores after 30 minutes will be measured. Pain will be assessed by masked observers, using the CHEOPS scale. Pain is rated:
every 15 minutes for the next hour
if applicable, hourly until discharge home</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>subtenons anesthetic and topical control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical anesthetic and subtenons control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical control and subtenons control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subtenons anesthetic - preservative-free bupivacaine 0.75%</intervention_name>
    <arm_group_label>subtenons anesthetic and topical control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel</intervention_name>
    <arm_group_label>topical anesthetic and subtenons control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical control - 0.5 cc of Hypromellose 0.3% gel</intervention_name>
    <arm_group_label>subtenons anesthetic and topical control</arm_group_label>
    <arm_group_label>topical control and subtenons control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subtenons control - 0.5 cc of Normal Saline</intervention_name>
    <arm_group_label>topical anesthetic and subtenons control</arm_group_label>
    <arm_group_label>topical control and subtenons control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 1 year to &lt; 8 years

          -  Undergoing  strabismus surgery under general anesthesia

          -  No previous surgery on muscle to be operated

          -  No known allergy to lidocaine or bupivacaine

          -  Investigator willing to inject subtenons NS or preservative-free        bupivacaine
             0.75% by cannula into all surgical wounds and willing to administer topical lidocaine
             3.5% ophthalmic gel or Hypromellose 0.3% gel (GenTeal Severe Dry Eye Relief) to all
             surgical wounds at the end of strabismus surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Enyedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Enyedi, MD</last_name>
    <phone>919-684-2038</phone>
    <email>laura.enyedi@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Enyedi, MD</last_name>
      <phone>919-684-2038</phone>
      <email>laura.enyedi@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
